PC-030 · GLP-1 · survodutide
Survodutide
BI 456906
Also: Dual GLP-1/GCGR
§ Overview
A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Survodutide represents a different approach to metabolic disease by combining GLP-1 effects with glucagon's ability to increase energy expenditure and reduce liver fat. Showing strong results in NASH/MASH clinical trials.
§ Mechanism
Dual agonism of GLP-1 receptor (appetite suppression, glucose control) and glucagon receptor (energy expenditure increase, hepatic fat reduction, amino acid metabolism). The glucagon component specifically targets liver fat, making it promising for NASH/MASH.
§ Common Uses
- → NASH/MASH treatment
- → Weight loss
- → Type 2 diabetes
- → Liver fat reduction
§ Reported Side Effects
- · Nausea
- · Diarrhea
- · Vomiting
- · Decreased appetite
- · Constipation
§ Research, Experiences & Trends
Mechanism of Action
Dual agonism of GLP-1 receptor (appetite suppression, glucose control) and glucagon receptor (energy expenditure increase, hepatic fat reduction, amino acid metabolism). The glucagon component specifically targets liver fat, making it promising for NASH/MASH.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Decreased appetite
- • Constipation